January 14, 2024- QuidelOrtho Corporation announced preliminary unaudited revenue for the fourth quarter ended December 29, 2024. The Company expects total reported revenues for the fourth quarter of 2024 to be in the range of approximately $702 million to $707 million, which would be in line with its previously announced 2024 financial guidance, including Labs revenue which is also in line with expectations. Expected fourth quarter 2024 total reported revenues include:
- Respiratory reported revenue in the range of approximately $141 million to $143 million
- Non-respiratory reported revenue in the range of approximately $561 million to $563 million
The preliminary unaudited revenues described herein are based on management’s initial analysis for the fourth quarter ended December 29, 2024 and are subject to adjustments based on the Company’s completion of its year-end financial close process.